Loading...
•
Mar 30
Pfizer Q1 2025 Earnings Report
Pfizer delivered solid results despite revenue declines compared to the prior year.
Key Takeaways
Pfizer posted a strong adjusted EPS and net income despite a revenue decrease driven by lower Paxlovid sales. Cost-saving initiatives and R&D productivity improvements bolstered performance.
First-quarter revenues totaled $13715000000, down 8% year-over-year.
Adjusted diluted EPS increased by 12% to $0.92.
Net income reached $2967000000, slightly down from $3115000000 last year.
Operational efficiency and cost-saving measures are trending toward the upper end of 2025 EPS guidance.
Pfizer
Pfizer
Pfizer Revenue by Segment
Revenue by Segment
Biopharma Revenue
CapyFin.comPfizer CentreOne Revenue
CapyFin.comPfizer Ignite Revenue
CapyFin.com Forward Guidance
Pfizer reaffirmed its full-year 2025 financial guidance, expecting revenues between $61000000000 and $64000000000 and adjusted diluted EPS between $2.80 and $3.00.
Positive Outlook
- Operational efficiency improvements are delivering cost savings.
- Strong R&D pipeline progress with new regulatory approvals and expansions.
- On track for $4.5B cost savings by 2025 with further productivity gains expected.
- Capital deployment focused on R&D and dividend payments.
- Expanded use of digital enablement and AI across operations.
Challenges Ahead
- Revenue impacted by sharp decline in Paxlovid sales.
- Higher manufacturer discounts due to Inflation Reduction Act affecting net prices.
- Unfavorable foreign exchange headwinds reduced revenues by 2%.
- Lower revenues from Eliquis and Xeljanz.
- Potential uncertainty from tariffs and trade policy changes not included in current guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income